Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Ablation of Intestinal Metaplasia Containing Dysplasia

Study:

Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years

Rationale:

n/a

Purpose:

The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing Barrett`s Esophagus.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Barrett Esophagus Device: Ablation System plus anti-secretory medication
Device: Sham procedure plus anti-secretory medication
N/A

Verified by BÂRRX Medical, Inc. July, 2012

Sponsored by: BÂRRX Medical, Inc.
Information provided by: BÂRRX Medical, Inc.
ClinicalTrials.gov identifier: NCT00282672

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

David S. Utley, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site